In a recent statement, Winnie Byanyima, head of UNAIDS, called on pharmaceutical company Gilead to 'make history' by allowing generic manufacturing of Lenacapavir, a new HIV drug. Byanyima believes that this move could bring an end to the AIDS pandemic. Lenacapavir is a highly effective, twice-yearly injectable antiretroviral medication that has the potential to reach the hardest-to-reach populations. By allowing generic manufacturing and implementing tiered pricing, Gilead could still turn a profit on Lenacapavir while making it more accessible and affordable to those in need. Byanyima also highlighted the importance of increased political will to conquer the AIDS pandemic and warned against pushbacks on LGBTQ rights, reproductive rights, and gender equality [4b837dcc].
This call from the UN comes in the context of the report on US investment in global health research and development, which highlights the significant returns and impact of public funding in combating diseases like HIV. The report emphasizes the need for continued investment in research and development to address global health challenges and improve health outcomes worldwide [9fc65a47].
Gilead has previously stated that it is in talks with governments and organizations to reach its access goals. The company's decision on allowing generic manufacturing of Lenacapavir could have far-reaching implications in the fight against HIV/AIDS and the global effort to end the AIDS pandemic [4b837dcc].